Immune globulin 10% - Octapharma

Drug Profile

Immune globulin 10% - Octapharma

Alternative Names: 10% high purity immunoglobulin; 10% IVIG; NewGam; octagam 10%; Octagam® Immune Globulin Intravenous (Human) 10% Liquid Preparation; Panzyga

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Octapharma
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dermatomyositis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Immune thrombocytopenic purpura; Immunodeficiency disorders
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Dermatomyositis
  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Aug 2017 Phase-III clinical trials in Chronic inflammatory demyelinating polyradiculoneuropathy in USA, Australia, Czech Republic, Hungary, Romania (IV) (NCT02638207)
  • 17 May 2017 Immune globulin 10% - Octapharma receives Orphan Drug status for Dermatomyositis in USA
  • 27 Feb 2017 Phase-III clinical trials in Dermatomyositis (Treatment-experienced) in USA, Czech Republic, Germany, Hungary (IV) (NCT02728752)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top